Episomal vector with the capacity to deliver a large gene containing all the critical regulatory elements is ideal for gene therapy. Human artificial chromosomes (HACs) have the capacity to deliver an extremely large genetic region to host cells without integration into the host genome, thus preventing possible insertional mutagenesis and genomic instability. Duchenne muscular dystrophy (DMD) is caused by mutation in the extremely large dystrophin gene (2.4 Mb). We herein report the development of a HAC vector containing the entire human dystrophin gene (DYS-HAC) that is stably maintained in mice and human immortalized mesenchymal stem cells (hiMSCs). The DYS-HAC was transferred to mouse embryonic stem (ES) cells, and isoforms of the DYS-HAC-derived human dystrophin in the chimeric mice generated from the ES cells were correctly expressed in tissue-specific manner. Thus, this HAC vector containing the entire dystrophin gene with its native regulatory elements is expected to be extremely useful for future gene and cell therapies of DMD. 
IntroductIon
Duchenne muscular dystrophy (DMD) is a recessive, fatal, X-linked disorder mainly caused by the absence of the dystrophin protein in skeletal muscle as well as in other tissues such as brain, retina, and smooth muscle, in which isoforms of dystrophin are normally expressed. [1] [2] [3] [4] [5] Major current therapeutic approaches of DMD consist of (i) introducing (e.g., via viral or nonviral vectors) or repairing (e.g., via exon skipping) the genetic message, (ii) transplanting dystrophin-positive cells (e.g., via myoblast transplantation), or (iii) regulating synthesis of an endogenous gene product (e.g., via upregulation of utrophin gene expression). 6, 7 Several groups have reported various approaches to introduce genes for gene therapy. 8, 9 However, these vector systems have several clinical drawbacks including host genome integration, the limited ability to insert large genes, and an inappropriate expression. Random integration of the gene into the host genome may cause genomic instability and a misregulation of proximal gene loci adjacent to integration sites. 10, 11 Importantly, another possible problem is that an overexpression of a transgene can produce muscular dystrophy. 12 Therefore, an exact dosage of the transgene is needed to achieve a therapeutic result in muscle gene therapy. Another approach of gene therapy is exon skipping. Exon skipping, aiming to reading frame restoration, is a highly promising approach to convert the DMD phenotype into the milder Becker phenotype. However, exon skipping is a sequence-specific therapy which is not applicable to patients who have mutations in promoter regions or essential functional domains, and in the case of antisense oligonucleotides, the readministration will also be necessary as these compounds have a limited half-life. 7 For all these reasons, it would be desirable to target the dystrophin gene of DMD patients directly and permanently, independently from the nature of the mutation.
For more effective treatment of DMD, the development of a dystrophin expression vector that produces all isoforms of dystrophin may be required. Dystrophin gene encodes a number of tissue-specific isoforms of dystrophin including Dp427, Dp260, Dp140, Dp116, and Dp71 generated by transcription from at least seven promoters and also by alternative splicing. 13 Until now, no episomal vector containing the entire dystrophin genomic region has been reported, because of its extremely large size (2.4 Mb). 13, 14 Human artificial chromosome (HAC) is a highly promising gene delivery tool that possesses several advantages over conventional gene delivery systems. Like native chromosomes, HAC vectors have the capacity to replicate and segregate autonomously without integration into the host genome. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] In addition, HACs have the capacity to carry large genomic loci with their regulatory elements. 25 The ideal gene delivery vector for safe gene therapy should be structurally defined and should not contain extra genes. We therefore recently produced a HAC vector by deleting all of the In this study, we developed a HAC vector containing the entire human dystrophin gene including its all transcriptional regulatory elements (DYS-HAC). We confirmed that the multiple tissue-specific isoforms of human dystrophin were produced in mice containing the DYS-HAC, and the DYS-HAC was stably maintained in mice and cultured human cells. results targeted integration of a loxP site into the proximal loci to the dystrophin gene on a human X chromosome fragment We performed the following experiments to develop a HAC containing the entire dystrophin gene using the chromosome engineering. The overall strategy for vector construction is shown schematically in Figure 1 . We have previously established monochromosomal hybrids containing individual human chromosomes. 26 In this study, a human X chromosome fragment was transferred from A9 cells into DT40 cells by microcell-medicated chromosome transfer (MMCT), because DT40 cells exhibit a high frequency of homologous recombination between an exogenous DNA template and its chromosomal counterparts. 27 This human X chromosome fragment containing the dystrophin gene was originally derived from the human primary fibroblast cells by MMCT. Initially, to integrate a loxP site containing the drug-resistant marker blasticidin S deaminase (bsd) and the 3′ hypoxanthine phosphoribosyl transferase (HPRT) into the proximal loci to the human dystrophin gene, the loxP targeting vector, pDYS-H3 was introduced into the DT40 hybrid cells retaining a single copy of human X chromosome fragment tagged with the neomycinresistant gene (Figure 2a) . PCR analyses using the primers (BsdR/ DloxP3R, DloxP4L/4R and DloxP5L/DloxP3R) showed that 2 of 11 blasticidin S Hydrochloride (BS)-resistant transfectants were correctly targeted (Tables 1 and 2) . By fluorescence in situ hybridization (FISH), the digoxigenin-labeled human Cot1 DNA probe localized to an independently segregating X chromosome fragment and the biotin-labeled bsd probe localized at the proximal region on the human X chromosome fragment. Neither insertion nor translocation were observed in both clones (Figure 2c and Table 2 ). These results indicate that the loxP site was successfully targeted in the correct location. These two clones were used for a targeted truncation of the distal region of the dystrophin gene on this human X chromosome fragment. 
targeted truncation of the distal region of the dystrophin gene on the human X chromosome
The terminal regions from the dystrophin gene on the X chromosome fragment were deleted in DT40 cells using the telomereassociated chromosome truncation, which is the combined use of gene targeting and telomere-mediated chromosome breakage to generate a defined truncation of a human chromosome. 16, 28 A targeting construct containing the region homologous to the distal region of the dystrophin gene, the selectable marker gene, puromycin and 1 kb of telomeric sequence repeats, pDYS-tel2, was transfected to the DT40 cells containing the loxP site-targeted human X chromosome fragment (Figure 2b) . Two hundred and sixty-five puromycin-resistant transfectants were isolated and first screened by PCR analyses with primers for the detection of the distal region (PRKX F/R and FTHL17 F/R). Eighteen of 265 clones showed the expected patterns of marker retention. Next, four of eight clones randomly selected among them showed the expected pattern of marker retention by PCR analyses with all other primers (Figure 2b , Tables 1 and 2 ). FISH analysis with the biotin-labeled PGK-puro probe and the digoxigenin-labeled human Cot1 DNA probe revealed that the human X chromosome fragment was truncated at the distal region of the dystrophin gene and the fragment segregated independently without either host genome insertion or translocation in all four clones (Figure 2d ). These results indicate that the genes on the distal from the dystrophin gene were deleted at the defined locus by the telomere-associated chromosome truncation strategy.
transfer of the modified X chromosome fragment from the dt40 cells to the chinese hamster ovary (cHo) hybrids containing the HAc vector
The truncated X chromosome fragment containing the human dystrophin gene and the 3′ HPRT-loxP was transferred from the DT40 cells into the CHO cells containing the HAC vector including the 5′ HPRT-loxP using MMCT. Sixty G418-resistant CHO clones were obtained from three independent DT40 clones containing the modified X chromosome fragment as donor cells. PCR analyses with primer sets for the detection of the HAC and the modified X chromosome showed that 11 of 60 CHO hybrids retained both the HAC vector and the modified X chromosome ( Table 1) . FISH analyses showed the HAC vector and the modified X chromosome to be independently present in 9 of 10 clones randomly selected among them (Figure 2e and Table 2 ). The efficiency of MMCT from DT40 cells to CHO cells was 5 × 10 −6 , which is comparable to our previous results. 29 cloning of the human dystrophin gene into the HAc vector by a cre-mediated site-specific translocation In order to clone only the human dystrophin gene into the HAC vector containing a 5′ HPRT-loxP using the Cre-loxP system, CHO hybrids containing the HAC and the modified human X chromosome including a 3′ HPRT-loxP were transfected with the Cre-recombinase expression vector. Intra-and intermolecular recombination between two loxP sites is efficiently promoted using Cre-recombinase. 30 A loxP-mediated site-specific translocation reconstitutes a functional HPRT gene, which confers HAT-resistance. Fiftythree HAT-resistant CHO clones were obtained using two independent CHO hybrids. The translocation confirmed in 16 of 53 CHO clones by PCR analysis (Tables 1 and 2 ). In addition, FISH analysis confirmed that the bacterial artificial chromosome (BAC) probe signal containing the part of human dystrophin gene was Figure 1 . CHO, Chinese hamster ovary; ES, embryonic stem; HAC, human artificial chromosome; hiMSC, human immortalized mesenchymal stem cell; HPRT, hypoxanthine phosphoribosyl transferase; NA, not applicable due to detection of endogenous genome; NT, not tested.
hybridized with the DYS-HAC and the DYS-HAC was present as an independent minichromosme without integration into the host genome in all 11 clones randomly selected among them (Figure 2f and Table 2 ). These results indicate that the DYS-HAC was successfully developed by cloning the human dystrophin gene into the HAC vector.
Generation of mouse embryonic stem (es) cells containing the dYs-HAc vector and production of chimeric mice
To investigate whether the DYS-HAC vector shows physiological expression of the human dystrophin gene, we produced the chimeric mice containing the DYS-HAC vector. First, the DYS-HAC was transferred from the CHO hybrids into mouse ES cells using MMCT technique. Thirty BS-resistant ES clones were obtained using three independent CHO cells containing the DYS-HAC vector as donor cells. In 12 of 30 drug-resistant ES hybrids, the DYS-HAC loci were detected and the expected patterns were showed by PCR (Figure 3a and Table 1 ). A FISH analysis showed that independently segregating the DYS-HAC was observed without insertion into host genome and the karyotype of mouse backgrounds was normal in 7 of 12 ES hybrids which showed the expected patterns by PCR (Figure 3b and Table 2 ). The efficiency of MMCT from CHO hybrids to ES cells was 1.8 × 10 −7 . The protein produced from the cytomegalovirus enhancer/ chicken β-actin promoter driven EGFP gene on the DYS-HAC was detected in mouse ES cells containing the DYS-HAC by fluorescence microscopy (Figure 3c) . Three independent ES hybrids containing the DYS-HAC clones were used to produce viable chimeric mice. Chimeric mice with up to 60% coat color chimerism were produced. The germline transmission of the DYS-HAC to the progency mice was not observed using the chimeric mice (data not shown).
expression of the EGFP gene and the human dystrophin gene in various tissues of the chimeras
We examined the stability of the DYS-HAC and the human dystrophin gene expression from the DYS-HAC in four chimeric mice containing the DYS-HAC. The EGFP gene driven by chicken β-actin promoter on the DYS-HAC was expressed in all examined tissues of the chimeric mice including intestine, brain, kidney, spleen, liver, heart, lung, thymus, skeletal muscle, and uterus (Figure 4a) , suggesting that the DYS-HAC was stably maintained in vivo. To investigate whether the human dystrophin gene on the DYS-HAC vector was appropriately expressed, total RNAs from various tissues of the chimeras were analyzed by reverse transcription-PCR using three pairs of specific primers to detect the human dystrophin tissuespecific transcripts. Using the DYS140e1L/DYSe45R primer sets, transcripts of human dystrophin from the DYS-HAC chimera were found mainly in brain as well as those from human used as control. Using the primer pairs of DYS427me1L/1R and DYS427le1L/DYSe3R, transcripts of human dystrophin from the DYS-HAC chimera were detected mainly in the heart, skeletal muscle, and uterus, as well as in those from normal human, whereas the genomic dystrophin were detected in all examined tissues using the DYS427me1L/1R primer sets (Figure 4b,c) . An immunostaining analysis using human dystrophin-specific antibody showed the human dystrophin protein to be localized The EGFP gene on the DYS-HAC was expressed in all examined tissues of the chimeric mice (intestine, brain, kidney, spleen, liver, heart, lung, thymus, skeletal muscle, and uterus). (b) The positions of primers for detecting dystrophin isoforms are shown. The black boxes show exons. The sequence of the DYS427le1L primer is located at the Dp427l isoforms but not at the Dp427m isoforms. (c) The expression of the human dystrophin gene derived from the DYS-HAC in each tissue of the chimeric mice containing the DYS-HAC vector was detected by reverse transcription-PCR using three different sets of the human dystrophin-specific primers. EGFP and GAPDH were used as internal controls. cDNA from C57BL/6 mouse tissues and human cDNA were used as a negative and a positive control, respectively. DNA from the tissues of the chimera containing the DYS-HAC was used as a control. (d) An immunofluorescence analysis of muscle biopsies from the chimeras containing the DYS-HAC vector, stained with the anti-human dystrophin-specific antibody (red). C57BL/6 mouse muscle tissue was used as a negative control. The expression of the EGFP gene on the DYS-HAC was tracked by fluorescence microscopy. Representative photographs are shown.
at the sarcolemmal membrane in muscle (Figure 4d) . 14, 31, 32 These results suggested that the isoforms of human dystrophin gene on the DYS-HAC vector were tissue-specifically expressed in the mouse genetic background, and the protein of the human dystrophin was localized at the correct locus.
stability of the dYs-HAc vector in human cells
To investigate the stability of the DYS-HAC in human cell, the DYS-HAC was transferred into the human immortalized mesenchymal stem cells (hiMSCs). 33 Fourteen hiMSC hybrids were selected with BS, and four clones randomly selected among them were screened by PCR and FISH analyses. In two of four clones, successful transfer was observed (Tables 1 and 2, Figure 5a ). The stability of the DYS-HAC vector was tested in the human cell line using the two hiMSCs containing the DYS-HAC. The cell lines were split and maintained independently either in medium with BS or without any selection. The retention of the DYS-HAC vector in the two sublines (both with and without selection) was assessed in 100 interphases and 20 metaphases at 25, 50, 75, and 100 population-doubling levels by the FISH analysis. The retention rate of the DYS-HAC vectors in the hiMSCs background remained in almost 100% of interphases by 100 population-doubling levels even without the BS-selection (Figure 5b) . No rearrangement was observed in the metaphases at 100 population-doubling levels (data not shown). Silencing of EGFP gene expression on the DYS-HAC was not observed in the hiMSCs containing the DYS-HAC at 100 population-doubling levels (Figure 5c ). These results indicate that the DYS-HAC vector in the human cells is stable without integration into the host genomes even after long-term culture in vitro.
dIscussIon
We herein report the development of a HAC containing the entire dystrophin gene as a potential strategy for the treatment of DMD. The entire human dystrophin genome is unusually large and beyond the capability of viral vector systems. 6 One important advantage of the HAC system report here is no apparent size limitation of inserted transgenes. 34 We thus inserted the entire dystrophin gene within this HAC vector.
Dystrophin has a complicated regulation of expression system including proper levels of expression and important functional isoforms that require selective promoter usage and highly regulated RNA processing events. Previously reported vector systems drove expression of dystrophin by the heterologous promoters that produced only one dystrophin isoform, mainly the 427 kDa dystrophin isoform. 8 Since the DYS-HAC vector used here contains the entire dystrophin gene with all known regulatory elements, we found evidence that at least three dystrophin isoforms were produced. Recently, Hoen et al. reported the development of a yeast artificial chromosome vector containing the entire human dystrophin gene that was successfully introduced into mice. 35 However, yeast artificial chromosome vector systems require the random integration of the transgene into the host genome creating the possibility of alteration of gene regulation and genomic instability. 36 In contrast, this study demonstrates that the DYS-HAC can be maintained in host cells as an independent minichromosome without integration into the host genome. The DYS-HAC contains the entire dystrophin gene with all its known native regulatory elements and its copy number is one similarly to native dystrophin subjected to X-inactivation. Therefore, unlike other vector systems in which dystrophin expression was driven by heterologous promoters resulting in an aberrant protein steady state levels, 12 the dystrophin produced from the DYS-HAC vector is expressed at levels similar to native dystrophin expression levels and isoform production. More importantly, the DYS-HAC can be repeatedly used for transferring to different host cells, whereas the other systems are expected to cause different results in each host cell.
Regarding future DMD treatment strategies, the DYS-HAC may perhaps be introduced into several types of patient stem or progenitor cells for ex vivo therapy, e.g., induced pluripotent stem cells, mesoangioblasts, and mesenchymal stem cells. [37] [38] [39] [40] [41] The DYS-HAC also contains a "suicide" gene encoding the HSV-tk gene as a backup system to specifically eliminate cells containing this vector. The cells containing the DYS-HAC can be specifically killed by ganciclovir, for example, if they induce a cellular abnormality such as carcinogenesis after transplantation. In addition, the mice obtained by crossing dystrophin-deficient mice with mice containing the DYS-HAC can also be used for functional and genetic studies. Therefore, the DYS-HAC vector will be useful not only for the treatment of DMD genetic disorders, but also for applications in animal transgenesis.
In conclusion, the DYS-HAC vector system reported herein is a unique nonintegrating vector maintaining the ability to incorporate exceptionally large regions of DNA and is highly stably maintained as an episomal element in host cells. Although the transferring efficiency of chromosome via MMCT need to be improved for cells with a limited life span, the current technology is sufficient for isolation of the immortalized stem cells with HACs transferred by ex vivo. When the HAC vector meets more sophisticated technologies of cellular differentiation to come in a near future, this nonintegrated episomal vector will facilitate various gene and cell therapies. Thus, the construction of the DYS-HAC is an initial step for the DMD-gene therapy. Future studies using DMD animal models with autologous genetically corrected stem cells containing the DYS-HAC vector will elucidate the efficacy of ex vivo gene therapy.
MAterIAls And MetHods
Cell culture. The DT40 hybrid cells were maintained in Roswell Park Memorial Institute medium 1640 (Invitrogen, Carlsbad, CA) containing 10% fetal bovine serum (Biowest, Nuaillé, France), 1% chicken serum (Invitrogen), 50 µmol/l 2-mercaptoethanol (Sigma, St Louis, MO) and the appropriate antibiotics. The DT40 hybrids containing a single copy of human X chromosome fragment (a long arm deletion of X chromosome) were produced by MMCT from mouse A9 cells containing its fragment (established by Dr Hanaoka; unpublished) and maintained with 1.5 mg/ml G418 (Invitrogen). The HPRT-deficient CHO (JCRB0218) hybrids containing the HAC vector were constructed previously and maintained in Ham's F-12 nutrient mixture (Invitrogen) plus 10% fetal bovine serum with 8 µg/ml BS (Funakoshi, Tokyo, Japan). The HAC contains no endogenous genes, with modifications from the original one, 19 i.e., containing an EGFP gene and the HSV-tk gene. hiMSCs were maintained in Dulbecco's modified Eagle's medium (Sigma) supplemented with 10% fetal bovine serum. 33 Mouse ES cell culture (TT2-F, isolated from TT2) was performed as described previously.
26
Construction of targeting vectors. The targeting vector, pDYS-H3 for introducing 3′ HPRT-loxP/bsd/tk, was constructed as follows: two 2.6 kb and 6.1 kb fragments for homologous arms corresponding to human dystrophin locus in AL050305 were amplified by PCR using primers DloxP4L/4R (3.1 kb), 5′-TCCACACGCCCTTTGATAGGAATAGGAT-3′ and 5′-CATCTGAGGGTTTTGGTTCTCGGTTTTC-3′; DloxP5L/5R (6.6kb), 5′-TGGAGAGAGTGAAGAGGGAAGGAGGAAA-3′ and 5′-CA CCTGCAGAACTCTCCACCCAAAAGTA-3′, digested with either EcoRI or BglII and sub-cloned into the equivalent sites of pKO Scrambler V901 backbone vector (Lexicon Genetics, Woodlands, TX), respectively, which contained the following three selection/insertion cassettes between the EcoRI and BglII sites: a 2 kb fragment from pMC1-tk (Stratagene, La Jolla, CA) containing the HSV-tk gene, a 2.3 kb XbaI/AscI fragment from pKO SelectHPRT V820 (Lexicon Genetics) containing the part of human HPRT gene with loxP site inserted at XbaI site of intron B and a 1.3 kb XhoI fragment from pCMV/bsd (Invitrogen) encoding the bsd gene. For construction of the chromosome truncation vectors pDYS-tel2, a PCR product from the human dystrophin locus in AC006060 was amplified by PCR with the following primers DYSt5L/5R (8.8 kb), (5′-TAAGG ATCCCCCTCATTGTAGCGAAGAGCAGG-3′ and 5′-CTGAGCCCTCA CCAGAATCACCTTGATA-3′), digested with both EcoRI and BamHI (7.5 kb) and sub-cloned into the EcoRI/BamHI sites of pBS-TEL/Puro vector. MA). Amplifications were performed with an annealing temperature of 58 °C for 30-35 cycles and then the amplified fragments were resolved by electrophoresis on a 2% agarose gel, followed by staining with ethidium bromide. The primer sequences were as follows: for dystrophin, DYS 427me1L/DYS427me1R (211 bp), 5′-TTCCCCCTACAGGACTCAGA-3′ and 5′-TCTTCCCACCAAAGCATTTT-3′; DYS427le1L/DYSe3R (150 bp), 5′-CTCATGATGAAAGAGAAGATGTTCAA-3′ and 5′-CTGTCAGGCC TTCGAGGA-3′; DYS 140e1L/DYS e45R (189 bp), 5′-TGCTGGCTGC TCTGAACTAA-3′ and 5′-GGCTTCCCAATTTTTCCTGT-3′; for EGFP, EGFPL/R (479 bp), 5′-CCTGAAGTTCATCTGCACCA-3′ and 5′-TGCTC AGGTAGTGGTTGTCG; for GAPDH (mouse and human), RPC1/2, 5′-CCATCTTCCAGGAGCGAGA-3′ and 5′-TGTCATACCAGGAAA TGAGC-3′. For DNA transfection, FISH, generation of chimeric mice containing the DYS-HAC and immunofluorescence staining, see the Supplementary Materials and Methods.
suPPleMentArY MAterIAls
Supplementary Materials and Methods.
